7,8-二氢异喹啉-5(6h)-酮盐酸盐 | 103441-65-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 7,8-二氢异喹啉-5(6h)-酮盐酸盐
• 英文名称: 7,8-dihydro-5(6H)-isoquinolinone hydrochloride
• 英文别名: 7,8-Dihydroisoquinolin-5(6H)-one hydrochloride；7,8-dihydro-6H-isoquinolin-5-one;hydrochloride
• CAS: 103441-65-2
• 化学式: C₉H₉NO*ClH
• 分子量: 183.637
• InChiKey: XIFLOZYAKQKYHN-UHFFFAOYSA-N

物化性质

• 熔点：
  235-236 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.02
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  7,8-二氢异喹啉-5(6h)-酮盐酸盐 在 碳酸氢钠 作用下， 以 水 为溶剂， 生成 7,8-二氢-6H-异喹啉-5-酮
  参考文献：
  名称：

  EP1726590

  摘要：

  公开号：
• 作为产物：
  描述：

  四氢异喹啉 在 盐酸 、 potassium tert-butylate 、 水 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 反应 48.0h， 生成 7,8-二氢异喹啉-5(6h)-酮盐酸盐
  参考文献：
  名称：

  EP1726590

  摘要：

  公开号：

文献信息

• Cycloalkanopyridine derivative
  申请人：Takahashi Hirobumi

  公开号：US20070191419A1

  公开（公告）日：2007-08-16

  Provided are cycloalkanopyridine derivatives of formula [I]: [wherein the symbols are the same as those stated in the description]. The compounds act as a nociceptin receptor antagonist, and are useful as medicines for diseases associated with a nociceptin receptor, for example, as a reliever against tolerance to a narcotic analgesic; a reliever against dependence on or addiction to a narcotic analgesic; an analgesic enhancer; an antiobesitic or appetite suppressor; a treating or prophylactic agent for cognitive impairment and dementia/amnesia; an agent for treating developmental cognitive abnormality; a remedy for schizophrenia; an agent for treating neurodegenerative diseases; an anti-depressant or treating agent for affective disorder; a treating or prophylactic agent for diabetes insipidus; a treating or prophylactic agent for polyuria; or a remedy for hypotension.

  提供的是式[I]的环烷基吡啶衍生物：[其中符号与说明中所述相同]。这些化合物作为一种nociceptin受体拮抗剂，可用作与nociceptin受体相关的疾病的药物，例如作为缓解对麻醉镇痛剂的耐受性的药物；对麻醉镇痛剂的依赖或成瘾的缓解剂；镇痛增强剂；抗肥胖或食欲抑制剂；治疗或预防认知障碍和失忆症的药物；治疗发育性认知异常的药物；治疗精神分裂症的药物；治疗神经退行性疾病的药物；抗抑郁或治疗情感障碍的药物；治疗或预防尿崩症的药物；治疗或预防多尿症的药物；或治疗低血压的药物。
• TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES
  申请人：Vanotti Ermes

  公开号：US20100075998A1

  公开（公告）日：2010-03-25

  The present invention provides tricyclic indoles and (4,5-dihydro) indoles of the formula (I) or a pharmaceutically acceptable salt thereof: wherein the ring A represents a fused pyrazole, pyridine or pyrimidine, means either simple or double carbon-carbon bond and R 1 , R 2 and R 3 are as defined in the specification. Further objects of the invention are a process for the preparation of the compounds of the formula (I), pharmaceutical compositions comprising them and methods for treating cell proliferative disorders. As a matter of fact, the compounds of the formula (I) are useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, in particular Cdc7 and AKT kinase activity, like cancer.

  本发明提供了三环吲哚和（4,5-二氢）吲哚的公式（I）或其药学上可接受的盐：其中环A代表融合的吡唑、吡啶或嘧啶，表示单重或双重碳-碳键，R1、R2和R3如规范中所定义。本发明的进一步目标是公式（I）化合物的制备方法，包含它们的制药组合物以及治疗细胞增殖性疾病的方法。事实上，公式（I）化合物在治疗与失调的蛋白激酶活性有关的疾病，特别是Cdc7和AKT激酶活性，如癌症方面非常有用。
• Tricyclic indoles and (4,5-dihydro) indoles
  申请人：Nerviano Medical Sciences S.R.L.

  公开号：US08207180B2

  公开（公告）日：2012-06-26

  The present invention provides tricyclic indoles and (4,5-dihydro) indoles of the formula (I) or a pharmaceutically acceptable salt thereof: wherein the ring A represents a fused pyrazole, pyridine or pyrimidine, means either simple or double carbon-carbon bond and R1, R2 and R3 are as defined in the specification. Further objects of the invention are a process for the preparation of the compounds of the formula (I), pharmaceutical compositions comprising them and methods for treating cell proliferative disorders. As a matter of fact, the compounds of the formula (I) are useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, in particular Cdc7 and AKT kinase activity, like cancer.

  本发明提供了式(I)或其药学上可接受的盐的三环吲哚和(4,5-二氢)吲哚，其中环A代表融合的吡唑、吡啶或嘧啶，表示单一或双重碳-碳键，而R1、R2和R3如规范中所定义。本发明的进一步目的是提供式(I)化合物的制备方法、包含它们的制药组合物以及治疗细胞增殖障碍的方法。事实上，式(I)化合物在治疗与蛋白激酶活性失调有关的疾病，特别是Cdc7和AKT激酶活性，如癌症方面是有用的。
• CYCLOALKANOPYRIDINE DERIVATIVE
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1726590A1

  公开（公告）日：2006-11-29

  Provided are cycloalkanopyridine derivatives of formula [I]: [wherein the symbols are the same as those stated in the description]. The compounds act as a nociceptin receptor antagonist, and are useful as medicines for diseases associated with a nociceptin receptor, for example, as a reliever against tolerance to a narcotic analgesic; a reliever against dependence on or addiction to a narcotic analgesic; an analgesic enhancer; an antiobesitic or appetite suppressor; a treating or prophylactic agent for cognitive impairment and dementia/amnesia; an agent for treating developmental cognitive abnormality; a remedy for schizophrenia; an agent for treating neurodegenerative diseases; an anti-depressant or treating agent for affective disorder; a treating or prophylactic agent for diabetes insipidus; a treating or prophylactic agent for polyuria; or a remedy for hypotension.

  所提供的是式[I]的环烷吡啶衍生物： [其中符号与描述中的符号相同]。这些化合物具有痛觉素受体拮抗剂的作用，可作为治疗与痛觉素受体相关疾病的药物，例如，可作为麻醉镇痛剂耐受性的缓解剂；麻醉镇痛剂依赖或成瘾的缓解剂；镇痛增强剂；抗厌食或食欲抑制剂；治疗或预防认知障碍和痴呆/失忆症的药物；治疗发育性认知异常的药物；治疗精神分裂症的药物；治疗神经退行性疾病的药物；抗抑郁剂或治疗情感障碍的药物；治疗或预防糖尿病性尿崩症的药物；治疗或预防多尿症的药物；或治疗低血压的药物。
• WO2008/65054
  申请人：——

  公开号：——

  公开（公告）日：——